Standards in the diagnosis and treatment of sepsis;Standards in der diagnostik und therapie der sepsis

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 38, Issue 2, 2003, Pages 107-135

  Meier Hellmann, A ^a  

^a HELIOS KLINIKUM ERFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACTIVATED PROTEIN C; ADRENALIN; AFELIMOMAB; AMRINONE; ANTITHROMBIN III; C REACTIVE PROTEIN; CATECHOLAMINE; CORTICOSTEROID; CYTOKINE; DOBUTAMINE; DOPAMINE; DOPEXAMINE; DROTRECOGIN; ENOXIMONE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; METHYLENE BLUE; MILRINONE; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROCALCITONIN; PROSTACYCLIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VASOPRESSIN;

ADJUVANT THERAPY; CLINICAL TRIAL; COLLOID; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; CRYSTALLOID; DIAGNOSTIC TEST; FLUID THERAPY; HEMODIALYSIS; HEMOFILTRATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; META ANALYSIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; SEPSIS; SEPTIC SHOCK; TREATMENT INDICATION;

ADRENAL CORTEX HORMONES; CARDIOVASCULAR AGENTS; HEMOFILTRATION; HEMOGLOBINS; HUMANS; HYPERTONIC SOLUTIONS; PLASMA SUBSTITUTES; SEPSIS; TERMINOLOGY;

EID: 0037330138     PISSN: 09392661     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-36994     Document Type: Review

References (131)

1. From the Centers for Disease Control. Increase in National Hospital Discharge Survey rates for septicemia - United States, 1979-1987. JAMA 1990; 263: 937-938
2. Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR. Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA 1997; 278: 234-240
3. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997; 25: 1095-1100
4. Schottmüller H. Wesen und Behandlung der Sepsis. Verhandl Dt Kongress Inn Med, 1914: 257-280
5. Gramm HJ, Reinhart K. Sepsis und septischer Schock - Definition und Epidemiologie. In: Van Aken H, Reinhart K, Zimpfer M, (eds). ains Band 2: Intensivmedizin Stuttgart, New York: Thieme, 2001: 756-760
6. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655
7. Rangel Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273: 117-123
8. Rau B, Steinbach G, Gansauge F, Mayer JM, Grunert A, Beger HG. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut 1997; 41: 832-840
9. Selberg O, Hecker H, Martin M, Klos A, Bautsch W, Kohl J. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. Crit Care Med 2000; 28: 2793-2798
10. de Werra I, Jaccard C, Corradin SB, Chiolero R, Yersin B, Gallati H, Assicot M, Bohuon C, Baumgartner JD, Glauser MP, Heumann D. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997; 25: 607-613
11. Wanner GA, Keel M, Steckholzer U, Beier W, Stocker R, Ertel W. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit Care Med 2000; 28: 950-957
12. Lundberg JS, Perl TM, Wiblin T, Costigan MD, Dawson J, Nettleman MD, Wenzel RP. Septic shock: an analysis of outcomes for patients with onset on hospital wards versus intensive care units. Crit Care Med 1998; 26: 1020-1024
13. Connors AF Jr, Speroff T, Dawson NV, Thomas C, Harrell FE Jr, Wagner D, Desbiens N, Goldman L, Wu AW, Califf RM, Fulkerson WJ Jr, Vidaillet H, Broste S, Bellamy P, Lynn J, Knaus WA. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA 1996; 276: 889-897
14. von Spiegel T, Wietasch G, Bursch J, Hoeft A. HZV-Bestimmung mittels transpulmonaler Thermodilution. Eine Alternative zum Pulmonaliskatheter? Anaesthesist 1996; 45: 1045-1050
15. Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 1988; 94: 1176-1186
16. Tuchschmidt J, Fried J, Astiz M, Rackow E. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest 1992; 102: 216-220
17. Tuchschmidt J, Fried J, Swinney R, Sharma OP. Early hemodynamic correlates of survival in patients with septic shock. Crit Care Med 1989; 17: 719-723
18. 2 Collaborative Group. N Engl J Med 1995; 333: 1025-1032
19. Heyland DK, Cook DJ, King D, Kernerman P, Brun Buisson C. Maximizing oxygen delivery in critically ill patients: a methodologic appraisal of the evidence. Crit Care Med 1996; 24: 517-524
20. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330: 1717-1722
21. Desjars P, Pinaud M, Potel G, Tasseau F, Touze MD. A reappraisal of norepinephrine therapy in human septic shock. Crit Care Med 1987; 15: 134-137
22. Desjars P, Pinaud M, Bugnon D, Tasseau F. Norepinephrine therapy has no deleterious renal effects in human septic shock. Crit Care Med 1989; 17: 426-429
23. Hesselvik JF, Brodin B. Low dose norepinephrine in patients with septic shock and oliguria: effects on afterload, urine flow, and oxygen transport. Crit Care Med 1989; 17: 179-180
24. Martin C, Eon B, Saux P, Aknin P, Gouin F. Renal effects of norepinephrine used to treat septic shock patients. Crit Care Med 1990; 18: 282-285
25. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377
26. Bisonni RS, Holtgrave DR, Lawler F, Marley DS. Colloids versus crystalloids in fluid resuscitation: an analysis of randomized controlled trials. J Fam Pract 1991; 32: 387-390
27. Velanovich V. Crystalloid versus colloid fluid resuscitation: a meta-analysis of mortality. Surgery 1989; 105: 65-71
28. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: A systematic review of randomised trials. BMJ 1998; 316: 961-964
29. Roberts I. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Br Med J 1998; 317: 235-240
30. Third European Consensus Conference in Intensive Care Medicine. Tissue hypoxia: How to detect, how to correct, how to prevent. Societe de Reanimation de Langue Francaise. The American Thoracic Society. European Society of Intensive Care Medicine. Am J Respir Crit Care Med 1996; 154: 1573-1578
31. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409-417
32. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993; 269: 3024-3029
33. Bersten AD, Hersch M, Cheung H, Rutledge FS, Sibbald WJ. The effect of various sympathomimetics on the regional circulations in hyperdynamic sepsis. Surgery 1992; 112: 549-561
34. Vincent JL, van der Linden P, Domb M, Blecic S, Azimi G, Bernard A. Dopamine compared with dobutamine in experimental septic shock: relevance to fluid administration. Anesth Analg 1987; 66: 565-571
35. Gutierrez G, Clark C, Brown SD, Price K, Ortiz L, Nelson C. Effect of dobutamine on oxygen consumption and gastric mucosal pH in septic patients. Am J Respir Crit Care Med 1994; 150: 324-329
36. Silverman HJ, Tuma P. Gastric tonometry in patients with sepsis. Effects of dobutamine infusions and packed red blood cell transfusions. Chest 1992; 102: 184-188
37. Levy B, Bollaert PE, Lucchelli JP, Sadoune LO, Nace L, Larcan A. Dobutamine improves the adequacy of gastric mucosal perfusion in epinephrine-treated septic shock. Crit Care Med 1997; 25: 1649-1654
38. Neviere R, Mathieu D, Chagnon JL, Lebleu N, Wattel F. The contrasting effects of dobutamine and dopamine on gastric mucosal perfusion in septic patients. Am J Respir Crit Care Med 1996; 154: 1684-1688
39. Joly LM, Monchi M, Cariou A, Chiche JD, Bellenfant F, Brunet F, Dhainaut JF. Effects of dobutamine on gastric mucosal perfusion and hepatic metabolism in patients with septic shock. Am J Respir Crit Care Med 1999; 160: 1983-1986
40. Reinelt H, Radermacher P, Fischer G, Geisser W, Wachter U, Wiedeck H, Georgieff M, Vogt J. Effects of a dobutamine-induced increase in splanchnic blood flow on hepatic metabolic activity in patients with septic shock. Anesthesiology 1997; 86: 818-824
41. Duke GJ, Briedis JH, Weaver RA. Renal support in critically ill patients: low-dose dopamine or low-dose dobutamine? Crit Care Med 1994; 22: 1919-1925
42. Shoemaker WC, Appel PL, Kram HB. Oxygen transport measurements to evaluate tissue perfusion and titrate therapy: dobutamine and dopamine effects. Crit Care Med 1991; 19: 672-688
43. Meier-Hellmann A, Reinhart K. Cardiovascular support by hemodynamic subset: Sepsis. In: Pinsky MR (ed.). Applied Cardiovascular Physiology. Springer-Verlag, Berlin, 1997: 230-245
44. Bollaert PE, Bauer P, Audibert G, Lambert H, Larcan A. Effects of epinephrine on hemodynamics and oxygen metabolism in dopamine-resistant septic shock. Chest 1990; 98: 949-953
45. Moran JL, O'Fathartaigh MS, Peisach AR, Chapman MJ, Leppard P. Epinephrine as an inotropic agent in septic shock: a dose-profile analysis. Crit Care Med 1993; 21: 70-77
46. Meier-Hellmann A, Reinhart K, Bredle DL, Specht M, Spies CD, Hannemann L. Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 1997; 25: 399-404
47. Levy B, Bollaert PE, Charpentier C, Nace L, Audibert G, Bauer P, Nabet P, Larcan A. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: A prospective, randomized study. Intensive Care Med 1997; 23: 282-287
48. Lherm T, Troche G, Rossignol M, Bordes P, Zazzo JF. Renal effects of low-dose dopamine in patients with sepsis syndrome or septic shock treated with catecholamines. Intensive Care Med 1996; 22: 213-219
49. Giraud GD, MacCannell KL. Decreased nutrient blood flow during dopamine- and epinephrine-induced intestinal vasodilation. J Pharmacol Exp Ther 1984; 230: 214-220
50. Meier-Hellmann A, Bredle DL, Specht M, Spies C, Hannemann L, Reinhart K. The effects of low dose dopamine on splanchnic blood flow and oxygen uptake in patients with septic shock. Intensive Care Med 1997; 23: 31-37
51. van den Berghe G, de Zegher F. Anterior pituitary function during critical illness and dopamine treatment. Crit Care Med 1996; 24: 1580-1590
52. Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994; 272: 1354-1357
53. Hannemann L, Reinhart K, Grenzer O, Meier-Hellmann A, Bredle DL. Comparison of dopamine to dobutamine and norepinephrine for oxygen delivery and uptake in septic shock. Crit Care Med 1995; 23: 1962-1970
54. Hollenberg SM, Ahrens TS, Astiz ME, Chalfin DB, Dasta JF, Heard SO, Martin C, Susla GM, Vincent JL. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Crit Care Med 1999; 27: 639-660
55. Sprung CL, Bernard GR, Dellinger RP. Guidelines for the management of severe sepsis and septic shock. Intensive Care Med 2001; 27: 1-134
56. Leier CV. Regional blood flow responses to vasodilators and inotropes in congestive heart failure. Am J Cardiol 1988; 62: 86E-93E
57. Kiefer P, Tugtekin I, Wiedeck H, Bracht H, Geldner G, Georgieff M, Radermacher P. Effect of a dopexamine-induced increase in cardiac index on splanchnic hemodynamics in septic shock. Am J Respir Crit Care Med 2000; 161: 775-779
58. Cain SM, Curtis SE. Systemic and regional oxygen uptake and delivery and lactate flux in endotoxic dogs infused with dopexamine. Crit Care Med 1991; 19: 1552-1560
59. Temmesfeld-Wollbrück B, Szalay A, Mayer K, Olschewski H, Seeger W, Grimminger F. Abnormalities of gastric mucosal oxygenation in septic shock: Partial responsiveness to dopexamine. Am J Respir Crit Care Med 1998; 157: 1586-1592
60. Scheeren TW, Schwarte LA, Loer SA, Picker O, Fournell A. Dopexamine but not dopamine increases gastric mucosal oxygenation during mechanical ventilation in dogs. Crit Care Med 2002; 30: 881-887
61. Tighe D, Moss R, Heywood G, al Saady N, Webb A, Bennett D. Goal-directed therapy with dopexamine, dobutamine, and volume expansion: effects of systemic oxygen transport on hepatic ultrastructure in porcine sepsis. Crit Care Med 1995; 23: 1997-2007
62. Lund N, de Asla RJ, Cladis F, Papadakos PJ, Thorborg PA. Dopexamine hydrochloride in septic shock: effects on oxygen delivery and oxygenation of gut, liver, and muscle. J Trauma 1995; 38: 767-775
63. Schmidt H, Secchi A, Wellmann R, Bach A, Bhrer H, Martin E. Dopexamine maintains intestinal villus blood flow during endotoxemia in rats. Crit Care Med 1996; 24: 1233-1237
64. Smithies M, Yee TH, Jackson L, Beale R, Bihari D. Protecting the gut and the liver in the critically ill: effects of dopexamine. Crit Care Med 1994; 22: 789-795
65. Maynard ND, Bihari DJ, Dalton RN, Smithies MN, Mason RC. Increasing splanchnic blood flow in the critically III. Chest 1995; 108: 1648-1654
66. Meier-Hellmann A, Bredle DL, Specht M, Hannemann L, Reinhart K. Dopexamine increases splanchnic blood flow but decreases gastric mucosal pH in severe septic patients treated with dobutamine. Crit Care Med 1999; 27: 2166-2171
67. Uusaro A, Ruokonen E, Takala J. Gastric mucosal pH does not reflect changes in splanchnic blood flow after cardiac surgery. Br J Anaesth 1995; 74: 149-154
68. Levy B, Nace L, Bollaert PE, Dousset B, Mallie JP, Larcan A. Comparison of systemic and regional effects of dobutamine and dopexamine in norepinephrine-treated septic shock. Intensive Care Med 1999; 25: 942-948
69. Kern H, Schroder T, Kaulfuss M, Martin M, Kox WJ, Spies CD. Enoximone in contrast to dobutamine improves hepatosplanchnic function in fluid-optimized septic shock patients. Crit Care Med 2001; 29: 1519-1525
70. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002; 359: 1209-1210
71. Dunser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, Luckner G, Mutz NJ, Hasibeder WR. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2001; 93: 7-13
72. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29: 487-493
73. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001; 27: 1416-1421
74. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96: 576-582
75. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95: 1122-1125
76. Varga C, Pavo I, Lamarque D, Szepes Z, Kiss J, Karacsony G, Laszlo FA, Laszlo F. Endogenous vasopressin increases acute endotoxin shock-provoked gastrointestinal mucosal injury in the rat. Eur J Pharmacol 1998; 352: 257-261
77. Klinzing S, Schiergens V, Reinhart K, Meier-Hellmann A. Could vasopressin be an alternative for vasopressor therapy in sepsis? Eur J Anaesthesiol 2002; 19 (Suppl. 24): 169
78. Hannemann L, Korell R, Meier-Hellmann A, Reinhart K. Hypertone Losungen auf der Intensivstation. Zentralbl Chir 1993; 118: 245-249
79. Kreimeier U, Frey L, Dentz J, Herbel T, Messmer K. Hypertonic saline dextran resuscitation during the initial phase of acute endotoxemia: effect on regional blood flow. Crit Care Med 1991; 19: 801-809
80. Kreimeier U, Messmer K. Zum Einsatz hypertoner Kochsalzlösungen in der Intensiv- und Notfallmedizin - Entwicklungen und Perspektiven. Klin Wochenschr 1991; 69 (Suppl 26): 134-142
81. Kiefer P, Tugtekin I, Wiedeck H, Bracht H, Vogt J, Wachter U, Weiss M, Altin C, Georgieff M, Radermacher P. Hepato-splanchnic metabolic effects of the stable prostacyclin analogue iloprost in patients with septic shock. Intensive Care Med 2001; 27: 1179-1186
82. Lehmann C, Taymoorian K, Wauer H, Krausch D, Birnbaum J, Kox WJ. Effects of the stable prostacyclin analogue iloprost on the plasma disappearance rate of indocyanine green in human septic shock. Intensive Care Med 2000; 26: 1557-1560
83. Scheeren T, Radermacher P. Prostacyclin (PG12): new aspects of an old substance in the treatment of critically ill patients. Intensive Care Med 1997; 23: 146-158
84. Reinhart K, Spies CD, Meier-Hellmann A, Bredle DL, Hannemann L, Specht M, Schaffartzik W. N-acetylcysteine preserves oxygen consumption and gastric mucosal pH during hyperoxic ventilation. Am J Respir Crit Care Med 1995; 151: 773-779
85. Spies CD, Reinhart K, Witt I, Meier-Hellmann A, Hannemann L, Bredle DL, Schaffartzik W. Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study. Crit Care Med 1994; 22: 1738-1746
86. Rank N, Michel C, Haertel C, Lenhart A, Welte M, Meier-Hellmann A, Spies C. N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study. Crit Care Med 2000; 28: 3799-3807
87. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endotheliumderived relaxing factor. Am J Physiol 1986; 250: H822-H827
88. Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991; 324: 1852-1857
89. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6: 593-597
90. Allman KG, Stoddart AP, Kennedy MM, Young JD. L-arginine augments nitric oxide production and mesenteric blood flow in ovine endotoxemia. Am J Physiol 1996; 271: H1296-H1301
91. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338: 1557-1558
92. Wright CE, Rees DD, Moncada S. Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 1992; 26: 48-57
93. Cobb JP, Natanson C, Quezado ZM, Hoffman WD, Koev CA, Banks S, Correa R, Levi R, Elin RJ, Hosseini JM. Differential hemodynamic effects of L-NMMA in endotoxemic and normal dogs. Am J Physiol 1995; 268: H1634-H1642
94. Schneider F, Lutun P, Hasselmann M, Stoclet JC, Tempe JD. Methylene blue increases systemic vascular resistance in human septic shock. Preliminary observations. Intensive Care Med 1992; 18: 309-311
95. Brown G, Frankl D, Phang T. Continuous infusion of methylene blue for septic shock. Postgrad Med J 1996; 72: 612-614
96. Zaloga GP. Early enteral nutritional support improves outcome: hypothesis or fact? Crit Care Med 1999; 27: 259-261
97. Heyland DK, Cook DJ, Guyatt GH. Enteral nutrition in the critically ill patient: a critical review of the evidence. Intensive Care Med 1993; 19: 435-442
98. Marik PE, Zaloga GP. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med 2001; 29: 2264-2270
99. Griffiths RD, Jones C, Palmer TE. Six-month outcome of critically ill patients given glutamine-supplemented parenteral nutrition. Nutrition 1997; 13: 295-302
100. Roth E, Spittler A, Oehler R. Glutamin: Wirkungen auf das Immunsystem, auf Eiweisshaushalt und Darmfunktionen. Wien Klin Wochenschr 1996; 108: 669-676
101. Kemen M, Senkal M, Homann HH, Mumme A, Dauphin AK, Baier J, Windeler J, Neumann H, Zumtobel V. Early postoperative enteral nutrition with arginine-omega-3 fatty acids and ribonucleic acid-supplemented diet versus placebo in cancer patients: an immunologic evaluation of Impact. Crit Care Med 1995; 23: 652-659
102. Daly JM, Lieberman MD, Goldfine J, Shou J, Weintraub F, Rosato EF, Lavin P. Enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids in patients after operation: immunologic, metabolic, and clinical outcome. Surgery 1992; 112: 56-67
103. Heyland DK, Cook DJ, Guyatt GH. Does the formulation of enteral feeding products influence infectious morbidity and mortality rates in the critically ill patients? A critical review of the evidence. Crit Care Med 1994; 22: 1192-1202
104. Beale RJ, Bryg DJ, Bihari DJ. Immunonutrition in the critically ill: a systematic review of clinical outcome. Crit Care Med 1999; 27: 2799-2805
105. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-658
106. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317: 659-665
107. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26: 645-650
108. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27: 723-732
109. Briegel J, Kellermann W, Forst H, Haller M, Bittl M, Hoffmann GE, Buchler M, Uhl W, Peter K. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clin Investig 1994; 72: 782-787
110. Annane D. Effects of the combination of hydrocortisone (HC) - fludrocortisone (FC) on mortality in septic shock. JAMA, 2002
111. Grootendorst AF, van Bommel EF. The role of hemofiltration in the critically-ill intensive care unit patient: present and future. Blood Purif 1993; 11: 209-223
112. Grootendorst AF, van Bommel EF, van Leengoed LA, van Zanten AR, Huipen HJ, Groeneveld AB. Infusion of ultrafiltrate from endotoxemic pigs depresses myocardial performance in normal pigs. J Crit Care 1993; 8: 161-169
113. Grootendorst AF, van Bommel EF, van der Hoven B, van Leengoed LA, van Osta AL. High volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pig. Intensive Care Med 1992; 18: 235-240
114. Lee PA, Matson JR, Pryor RW, Hinshaw LB. Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1993; 21: 914-924
115. Lange R, Erhard J, Sander A, Scherer R, Eigler F. Der Einsatz der kontinuierlichen veno-venösen Hochvolumen-Hämofiltration (CVVHVH) bei Patienten im Multiorganversagen. Prinzip und Anwendung. Zentralbl Chir 1996; 121: 535-540
116. Storck M, Hartl WH, Zimmerer E, Inthorn D. Comparison of pump-driven and spontaneous continuous haemofiltration in postoperative acute renal failure. Lancet 1991; 337: 452-455
117. Cole L, Bellomo R, Hart G, Journois D, Davenport P, Tipping P, Ronco C. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002; 30: 100-106
118. Ullrich H, Jakob W, Frohlich D, Rothe G, Prasser C, Drobnik W, Taeger K, Meier-Hellmann A, Reinhart K, Zimmermann M, Schmitz G. A new endotoxin adsorber: first clinical application. Ther Apher 2001; 5: 326-334
119. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119: 771-778
120. Debets JM, Kampmeijer R, van der Linden MP, Buurman WA, van der Linden CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17: 489-494
121. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869-871
122. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/ TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-664
123. Panacek EA, Marshall J, Fischkoff S, Barchuk W, Teoh L. Neutralization of TNF by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis: Results of the MONARC trial. Chest 2000; 118: S88
124. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-1878
125. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709
126. Alejandria MM, Langsang MA, Dans LF. Intravenous immunglobulin for treating sepsis and septic shock. The Cochrane Library 2. 2001; Oxford: Update Software
127. Callaham ML, Wears RL, Weber EJ, Barton C, Young G. Positive-outcome bias and other limitations in the outcome of research abstracts submitted to a scientific meeting. JAMA 1998; 280: 254-257
128. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337: 867-872
129. Werdan K, Pilz G and the SB1T Study group. Polyvalent immune globulins. Shock 1987; 7 (5): 1918
130. Sibbald WJ, Vincent JL. Round table conference on clinical trials for the treatment of sepsis. Crit Care Med 1995; 23: 394-399
131. Gutierrez G, Palizas F, Doglio G, Wainsztein N, Gallesio A, Pacin J, Dubin A, Schiavi E, Jorge M, Pusajo J. Gastric intramucosal pH as a therapeutic index of tissue oxygenation in critically ill patients. Lancet 1992; 339: 195-199